Table 1.
Comparison of cerebral hAβ levels in vehicle-treated and 1,25(OH)2D3-treated Tg mice
| Vehicle or 1,25(OH)2D3 treatment (μg/kg, i.p.) | Soluble Aβ concentration in brain (ng/g wet weight) |
Insoluble Aβ concentration in brain (ng/g wet weight) |
||||
|---|---|---|---|---|---|---|
| hAβ1–40 | hAβ1–42 | hAβ1–42/hAβ1–40 ratio | hAβ1–40 | hAβ1–42 | hAβ1–42/hAβ1–40 ratio | |
| Tg2576 (5 males per group), began treatment at 10 weeks old, 11 weeks old when killed | ||||||
| 0 (q2d × 4) | 39.1 ± 4.25 | 11.1 ± 0.240 | 0.276 ± 0.0169 | NPb | NP | NP |
| 2.5 (q2d × 4) | 15.4 ± 2.15* | 5.82 ± 0.891* | 0.357 ± 0.0226 | NP | NP | NP |
| TgCRND8 (4 males, 3–4 females per group), began treatment at 9 weeks old, 17 weeks old when killed | ||||||
| 0 (q3d × 19) | 872 ± 33.7 | 3360 ± 122 | 3.65 ± 0.176 | 923 ± 66.7 | 4640 ± 143 | 4.75 ± 0.247 |
| 2.5 (q3d × 19) | 618 ± 18.7* | 2240 ± 153* | 3.39 ± 0.196 | 514 ± 69.0* | 3870 ± 133* | 7.16 ± 0.361* |
| TgCRND8 (4 females per group), began treatment at 20 weeks old, 21 weeks old when killed | ||||||
| 0 (q2d × 4) | 1060 ± 25.9 | 2920 ± 202 | 2.78 ± 0.219 | 3850 ± 931 | 18000 ± 1700 | 3.83 ± 0.166 |
| 2.5 (q2d × 4) | 675 ± 54.3** | 1970 ± 130** | 3.04 ± 0.417 | 4710 ± 282 | 16500 ± 878 | 3.54 ± 0.312 |
| 2.5 (q2d × 4) + 10 mg/kg elacridar (q12h × 8) | 1240 ± 27.6*** | 4700 ± 214*** | 3.78 ± 0.107*** | 6030 ± 238 | 20400 ± 443 | 3.40 ± 0.198 |
hAβ levels were not detected in non-Tg mice. NP, Not present.
*p < 0.05 for 1,25(OH)2D3 treatment compared with vehicle treatment, Student's two-tailed t test.
**p < 0.05 for 1,25(OH)2D3 treatment compared with vehicle treatment, one-way ANOVA with Bonferroni's multiple comparisons test.
***p < 0.05 for elacridar plus 1,25(OH)2D3 treatment compared with vehicle treatment, one-way ANOVA with Bonferroni's multiple comparisons test.